Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A166 in Advanced HER2-expressing Solid Tumors
NCT05311397Phase 1Completed
- Sponsor
- Kelun-Biotech
- Start
- Aug 2018
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab botidotin in breast cancer and solid tumor (2 arms), sponsored by Kelun-Biotech. Primary endpoint: Objective Response Rate at 24 months. Started Aug 2018; status: completed.
02
Drugs
trastuzumab botidotin
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05311397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311397.